New pill aims to tame liver damage from hepatitis b
NCT ID NCT07417553
First seen Feb 19, 2026 · Last updated May 25, 2026 · Updated 10 times
Summary
This study tests a drug called Hydronidone in 150 adults with liver scarring caused by chronic hepatitis B. Participants take the drug three times daily for 28 days to see if it is safe. The goal is to manage the disease, not cure it, as patients must continue their usual antiviral treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B-RELATED LIVER FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing Medical University Second Affiliated Hospital
RECRUITINGChongqing, Chongqing Municipality, 400000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.